Orally administered medical device for the safe reduction of blood sugar levels without uptake into the body
The Company’s lead product candidate, SiPore™, is an orally-administered medical device for the safe reduction of blood sugar levels in people at risk of developing diabetes, prediabetics, and newly diagnosed type 2 diabetics. The device is a tasteless and odourless white powder taken with water. A First in Man clinical trial of SiPore™ showed significant reductions in a range of metabolic parameters and an excellent safety profile.
SiPore™ has undergone clinical testing confirming its safety and performance.
How SiPore™ works
SiPore™ has been developed with optimal safety in mind. Designed to act locally in the gut, the device consists of precisely engineered micron-sized silica particles with tailored porosity. Inside the gut, the particles work as a molecular sieve by mechanically separating digestive enzymes from undigested food, thereby improving metabolic health through a gentle mode of action. The particles pass through the body without being absorbed and are safely eliminated in the same manner as food.
Extensive preclinical studies and clinical development in-house and in collaboration with external research groups clearly demonstrates the safety and performance of SiPore™.
”SiPore™ is designed with safety and sustainability in mind. It is made of pure silica, a natural mineral made of silicon and oxygen, two of the earth’s most abundant elements. SiPore™ derives its function from its unique architecture and chemistry. It is gentle to the human body as to the environment.Dr. Eric JohnstonCTO & Inventor
A Little Of Our Story
Sigrid Therapeutics has two patent families, covering the SiPore™ technology and its use in several clinical indications, and New Chemical Entity patent applications with compositional matter for SiPore™. The Company has granted patents in key territories and holds global rights to all patents and patent applications.
Sigrid also relies on know-how and trade secrets for our material production and on continuing technological innovation to develop and maintain our proprietary position on the market.